Merck Ends Talks to Buy Revolution Medicines; USA Rare Earth Surges; Nvidia Invests an Additional $2 Billion in CoreWeave
On this episode of Stock Movers:- Merck (MRK) is no longer in talks to acquire biotech firm Revolution Medicines (RVMD) after the two companies couldn’t agree on a price, the Wall Street Journal reported, citing people familiar with the matter.A deal could have valued Revolution Medicines at around $30 billion, the report said, adding that talks could restart or another suitor could emerge. Merck is seeking deals that will strengthen its treatments portfolio to counter patent losses that will erode sales by $18 billion over the next five years.- USA Rare Earth (USAR) shares rise after…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.